|
Global Pain Relieving Drug Market Analysis 2010-2025Übersetzung: Globale Marktnalyse fuer schmerzlindernde Medikamente 2010-2025
|
|||||||||||
| Zahlen und Fakten zur Studie: |
This report gives you the following benefits in particular: 150 seiten | |||||||||||
| Inhalt der Studie: |
In 2009, the global pain relieving drug market generated revenues over $50bn. From 2010, that sector will benefit from new drugs and reformulations of existing products. Cases of pain from many condit.....
In 2009, the global pain relieving drug market generated revenues over $50bn. From 2010, that sector will benefit from new drugs and reformulations of existing products. Cases of pain from many conditions are increasing rapidly. Worldwide, the treatment of pain is a priority for healthcare providers, with high demand for drugs. Where is the pain relieving drug market heading - technologically and commercially - from 2010 onwards? Our new report - Global Pain Relieving Drug Market Analysis 2010-2025 - explains how this market will develop, and where the opportunities will lie. We show how you can benefit from its developments and potential. There remains unmet therapeutic needs in the treatment of pain. Many conditions have no pain relievers designed for relieving their symptoms, or very few. Side effects and safety constitute a challenge for drug developers. There is also increasing demand for pain treatments in developing countries. Novel compounds that show improved safety – with high efficacy – can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2025, our new report explains how you can benefit from this opportunity. Global Pain Relieving Drug Market 2010-2025 covers the following therapeutic categories: • Narcotics for pain • NSAIDs for pain • Treatments for arthritic pain • Treatments for migraine • Treatments for neuropathic pain • Local anaesthetics. What types of therapeutic agents are likely to enter the market from 2010 onwards, and will they dominate? Where do the main opportunities lie, and what are the drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in the global pain drug market. Comprehensive analysis of the global pain drug market Global Pain Relieving Drug Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 75 tables and figures included, as well as two original interviews with experts which are unavailable elsewhere. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Report Highlights Companies Listed AstraZeneca Abbott Laboratories Acura Pharmaceuticals Alpharma Pharmaceuticals Alza Corporation Almirall Anesiva Anesta Corporation Apotex Applied Pharma Research Archimedes Pharma Astellas Pharma Bayer HealthCare Pharmaceuticals Biovail Corporation Boehringer Ingelheim Bristol Myers Squibb Cephalon Cipher Pharmaceuticals CyDex Pharmaceuticals Daiichi Sankyo Dr. Reddy’s Laboratories DURECT Corporation Eisai EMEA Endo Laboratories Epicept Corporation Ethypharm Eurand Pharmaceuticals FDA Genentech Gruenenthal GlaxoSmithKline GW Pharmaceuticals Health Canada Hisamitsu Pharmaceutical Horizon Therapeutics International Association for the Study of Pain (IASP) Ikano Therapeutics Janssen Pharmaceutical Javelin Pharmaceuticals Johns Hopkins University Johnson & Johnson King Pharmaceuticals Kowa Pharmaceuticals Kyorin Pharmaceutical Labopharm Lundbeck Pharmaceuticals MAP Pharmaceuticals Meda Pharmaceuticals Merck & Co. Mylan Pharmaceuticals Napp Pharmaceutical Group National Institutes of Health (NIH) NicOx NorthStar Consulting LLC Novartis NuPathe Ono Pharmaceutical Company Pacira Pharmaceuticals Pain Therapeutics Paion Pfizer Plethora Solutions PLx Pharma Pozen Pharmaceuticals Purdue Pharma QRxPharma Ranbaxy Laboratories Ratiopharm Recordati Pharmaceuticals Roxro Pharma Sanofi-Aventis Shionogi Pharma SK Corporation SkyePharma STADA Pharmaceuticals Symbollon Pharmaceuticals Teva Pharmaceutical Industries UCB Pharma US Society for Neuroscience Valeant Pharmaceuticals WEX Pharmaceuticals Winston Pharmaceuticals World Health Organisation (WHO) Wyeth Pharmaceuticals ZARS Pharma Zogenix [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 The Pain Relieving Drug Market: Entering a Crucial Period 1.2 Aims, Scope and Format of the Report 1.3 Research & Analysis Methods 2. Introduction to Pain and its Treatment 2.1 What is Pain? 2.1.1 Historical Aspects of Pain 2.2 Pain Pathways 2.2.1 WHO Pain Ladder 2.3 Classification and Types of Pain 2.3.1 Acute Pain 2.3.2 Chronic Pain 2.3.2.1 Psychosocial Effects of Chronic Pain 2.3.2.2 The Financial Burden of Chronic Pain 2.3.2.3 Chronic Cancer Pain 2.3.2.4 Breakthrough Cancer Pain 2.4 Neuropathic Pain 2.4.1 Distinguishing Neuropathic Pain 2.5 Neurochemistry of Pain 2.5.1 Prostaglandins 2.5.2 Opioids 2.6 Pain Treatments 2.7 OTC Pain Relievers 3. The Global Pain Pharmaceutical Market 2010-2025 3.1 The Global Pain Market: Analysis and Forecast 3.2 Sub-Market Categories of the Global Pain Drug Market 3.2.1 Oxycontin Currently Leads the Global Pain Drug Market 3.2.2 The Anti-Epileptics Segment: Will its Success Last? 3.3 Success in the Pain Relieving Drug Market Has Proved Challenging 3.4 While the Past Has Been Difficult for Pain Management, There is Optimism for the Future 4. The Global Narcotics Market 2010-2025 4.1 The Narcotics Market Analysis and Forecast 4.2 Oxycontin – Therapeutic and Commercial Challenges 4.2.1 Development of Oxycontin (Oxycodone) 4.3 Duragesic (Fentanyl) – Challenges in the Market 4.3.1 Development of Duragesic (Fentanyl) 4.4 Fentanyl MYLA Will Show Strong Revenues 4.4.1 Fentanyl 4.5 Actiq Fighting a Decline in Sales 4.5.1 Actiq (Fentanyl Citrate) 4.6 Other Agents 4.7 Total Sales in the Narcotics Market Will Increase, Despite its Being Crowded 5. The Global Non-Narcotics Market 2010-2025 5.1 The Non-Narcotics Market Analysis and Forecast 5.2 Efferalgan is Currently the Non-Narcotic Market's Leading Drug 5.2.1 Development of Efferalgan (Paracetamol/Acetaminophen) 5.3 Tylenol – a Future Blockbuster of the Non-Narcotics Market? 5.3.1 Development of Tylenol (Paracetamol/Acetaminophen) 5.4 Doliprane (Paracetamol/Acetaminophen) 5.5 Will Advil Exhibit Strong Growth? 5.5.1 Advil (Ibuprofen) 5.6 Aspirin Bayer – Line Extensions Keeping Sales Up 5.6.1 Aspirin Bayer (Acetylsalicylic Acid) 5.7 Other Agents 6. The Global Arthritic Pain Drug Market 2010-2025 6.1 The Arthritic Pain Market Analysis and Forecast 6.1.1 Safety Issues for COX-2 Inhibitors 6.2 Pfizer's Celebrex Dominates the Market, but Will it Last? 6.2.1 Development of Celebrex (Celecoxib) 6.3 Voltaren Will Exhibit Strong Growth 6.3.1 Development of Voltaren (Diclofenac) 6.4 Arcoxia: Strong Growth over the Forecast Period? 6.4.1 Development of Arcoxia (Etoricoxib) 6.5 Loxonin: Sales in Developing Countries Aiding Growth 6.5.1 Loxonin (Loxoprofen) 6.6 Mobic Will Suffer from Generic Competition 6.6.1 Development of Mobic (Meloxicam) 6.7 Other Agents 6.8 Outlook for the Arthritis Pain Drug Market 7. The Global Migraine Market 2010-2025 7.1 The Migraine Drug Market Analysis and Forecast 7.2 GSK's Blockbuster Imitrex/Imigran Faces Revenue Decline 7.2.1 Development of Imitrex/Imigran (Sumatriptan) 7.3 Maxalt's Patent Expiry Will Affect Sales 7.3.1 Development of Maxalt (Rizatriptan) 7.4 Zomig's Decline in Sales 7.4.1 Development of Zomig (Zolmitriptan) 7.5 Relpax Will Exhibit Loss of Revenue from 2010-2025 7.5.1 Development of Relpax (Eletriptan) 7.6 Other Agents 7.7 What Does the Future Hold for Migraine Therapy? 7.8 Unmet Needs in the Treatment of Migraine 8. Neuropathic Pain and Local Anaesthetics Markets 2010-2025 8.1 Introduction 8.1.1 Anti-Epileptic Drugs Market 8.2 Anti-Epileptic Market Analysis and Forecast 8.2.1 Lyrica 8.2.2 The Development of Lyrica (Pregabalin) 8.2.3 Topamax (Topiramate): Impending Patent Expiry 8.2.4 Topamax: Challenges this Product has to Face 8.2.5 Other Agents 8.3 Local Anaesthetic Market Analysis and Forecast 8.3.1 Lidoderm (Lidocaine) Forecast 8.3.2 Lidoderm: Market Leader for the Local Anaesthetic Market 8.3.3 Other Agents 9. SWOT Analysis of the Global Pain Drug Market 9.1 SWOT Analysis 9.2 Market Drivers 9.3 Market Restraints 9.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors 9.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs 9.6 Patients Dependent on Reformulations of Existing Drugs 9.7 The Narcotics Market Suffers from Side Effects 9.8 Risk of Intestinal Bleeding Associated with NSAIDs 9.9 The Under-Treatment of Pain 9.10 How Will Those Findings Affect Commercial Prospects? 9.11 The Future of the Pain Market – Closing Comments 9.11.1 Improved Use of New and Existing Pain Management Therapies 9.11.2 Analgesic Effects of Established Drugs for Other Indications 9.11.3 Personalised Pain Management Therapy? 10. Geographical Breakdown of the Global Pain Market 2010-2025 10.1 The Pain Drug Market: Regional Sales Breakdown 10.2 Countries Leading the Global Pain Market, 2009 10.3 Pain Drug Sales in Major National Markets 10.3.1 The Pain Drug Market in the US 10.3.2 The Pain Drug Market in Germany 10.3.3 The Pain Drug Market in France 10.3.4 The Pain Drug Market in Japan 10.3.5 The Pain Drug Market in the UK 10.3.6 The Pain Drug Market in Canada 10.3.7 The Pain Drug Market in Spain 10.3.8 The Pain Drug Market in India 10.3.9 The Pain Drug Market in China 11. R&D Pipeline for the Treatment of Pain 11.1 The R&D Pipeline for the Pain Market is Large and Expanding 11.2 The Potential of the Pain Market Has Encouraged R&D 11.3 Innovation Rules for Early-Stage Pipeline Drugs 11.4 Late-Stage Pipeline Products in the Narcotics Sector 11.5 Late-Stage Pipeline Products in the Non-Narcotics Sector 11.6 Late-Stage Pipeline Products in the Anti-Arthritic Sector 11.7 Late-Stage Pipeline Products in the Anti-Migraine Sector 11.8 Late-Stage Pipeline Products in the Anti-Epileptic and Local Anaesthetic Sectors 11.9 The Pain Drug Pipeline Shows Short- and Long-Term Potential 12. Future Therapies 12.1 Cannabinoids and Pain: An Alternative to Opioids? 12.2 Experimentally-Induced Acute Pain 12.3 Post Surgical Acute Pain 12.4 Chronic Pain 12.5 Sativex 12.5.1 European Phase III Trials of Sativex 12.5.2 Sativex Approved for Cancer Pain 12.6 Cannabinoids and Pain: a Lucrative Market? 12.7 The Future of Pain Research 12.8 Advanced Drug Delivery 12.8.1 Delivery of Poorly-Soluble Drugs 12.8.2 Examples of Poorly-Soluble Drugs 13. Interviews with Experts 13.1 Interview with Dr William Schmidt (NorthStar Consulting LLC) 13.1.1 Growth of the Pain Market 13.1.2 New Targets in Pain Management 13.1.3 Unmet Needs in the Pain Market 13.1.4 Regulatory Hurdles in the Post-Vioxx Era 13.1.5 The Future of COX-2 Inhibitors 13.2 Interview with Dr Anastasia Liapi (Astellas Pharma Europe) 13.2.1 Assessing the Commercial Value of Novel Pain Therapies 13.2.2 Hurdles That Face New Launches in the Pain Market 13.2.3 Geographical Differences 14. Conclusions 14.1 The Pain Market is Achieving Sales Growth that Will Last 14.2 The Anti-Epileptics Market 14.3 The Narcotics Market 14.4 The Anti-Arthritic Market 14.5 The Anti-Migraine Market 14.6 Major Success in the Pain Drug Market Has Proved Challenging 14.7 Why Growth of the Pain Relieving Drug Market Will Continue [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 3.1 The Global Pain Drug Market: Sales Forecast ($m), 2009-2017 Table 3.2 The Global Pain Drug Market: Sales Forecast ($m), 2018-2025 Table 3.3 The Global Pain Drug Market: Sales ($m) and Market Shares (%) Forecasts 2009-2017 Table 3.4 The Global Pain Drug Market: Sales ($m) and Market Shares (%) Forecasts 2018-2025 Table 3.5 Top Ten Products in the Global Pain Treatments Market: Sales ($m), 2009 Table 4.1 The Global Narcotics Market: Sales Forecasts ($m), 2009-2017 Table 4.2 The Global Narcotics Market: Sales Forecasts ($m), 2018-2025 Table 5.1 The Global Non-Narcotics Market: Sales Forecasts ($m), 2009-2017 Table 5.2 The Global Non-Narcotics Market: Sales Forecasts ($m), 2018-2025 Table 6.1 The Global Anti-Arthritic Market: Sales Forecasts ($m), 2009-2017 Table 6.2 The Global Anti-Arthritic Market: Sales Forecasts ($m), 2018-2025 Table 7.1 The Global Anti-Migraine Market: Sales Forecasts ($m), 2009-2017 Table 7.2 The Global Anti-Migraine Market: Sales Forecasts ($m), 2018-2025 Table 8.1 The Global Anti-Epileptics Market: Sales Forecasts ($m), 2009-2017 Table 8.2 The Global Anti-Epileptics Market: Sales Forecasts ($m), 2018-2025 Table 8.3 The Global Local Anaesthetic Market: Sales Forecasts ($m), 2009-2017 Table 8.4 The Global Local Anaesthetic Market: Sales Forecasts ($m), 2018-2025 Table 9.1 SWOT Chart for the Global Pain Drug Market, 2010 Table 10.1 Global Pain Market Revenues ($m) and Shares (%) by Region, 2009 Table 10.2 Countries Leading the Pain Drug Market ($m), 2009 Table 10.3 Pain Market Sales Forecasts for the Leading Seven Countries ($m), 2009-2017 Table 10.4 Pain Market Sales Forecasts for the Leading Seven Countries ($m), 2018-2025 Table 10.5 Seven Major Country Market Shares (%), 2009, 2015 & 2025 Table 11.1 Late-Stage Narcotic Pipeline Agents, 2010 Table 11.2 Late-Stage Narcotic Pipeline Agents, 2010 (Continued) Table 11.3 Late-Stage Non-Narcotic Pipeline Agents, 2010 Table 11.4 Late-Stage Non-Narcotic Pipeline Agents, 2010 (Continued) Table 11.5 Late-Stage Anti-Arthritic Pipeline Agents, 2010 Table 11.6 Late-Stage Anti-Migraine Pipeline Agents, 2010 Table 11.7 Late-Stage Anti-Epileptic Pipeline Agents, 2010 Table 11.8 Late-Stage Local Anaesthetic Pipeline Agents, 2010 Figure 3.1 The Global Pain Drug Market: Sales Forecast ($m), 2010-2025 Figure 3.2 Leading Pain Market Segments: Sales Forecasts ($m), 2010-2025 Figure 3.3 Leading Pain Market Segments: Sales ($m) & Market Shares (%), 2009, 2015, 2010 & 2015 Figure 3.4 Leading Pain Markets: Market Shares (%), 2009 Figure 3.5 Leading Pain Markets' Market Shares (%), 2025 Figure 4.1 The Global Narcotics Market: Sales Forecast ($m), 2010-2025 Figure 4.2 Oxycontin Sales Forecast ($m), 2010-2025 Figure 4.3 Duragesic Sales Forecast ($m), 2010-2025 Figure 4.4 Fentanyl Myla Sales Forecast ($m), 2010-2025 Figure 4.5 Actiq Sales Forecast ($m), 2010-2025 Figure 4.6 Other Products: Sales Forecast ($m), 2010-2025 Figure 5.1 The Global Non-Narcotics Market: Sales Forecast ($m), 2010-2025 Figure 5.2 Efferalgan Sales Forecast ($m), 2010-2025 Figure 5.3 Tylenol Sales Forecast ($m), 2010-2025 Figure 5.4 Doliprane Sales Forecast ($m), 2010-2025 Figure 5.5 Advil Sales Forecast ($m), 2010-2025 Figure 5.6 Aspirin Bayer Sales Forecast ($m), 2010-2025 Figure 5.7 Others Agents: Sales Forecast ($m), 2010-2025 Figure 6.1 The Global Anti-Arthritic Market: Sales Forecast ($m), 2010-2025 Figure 6.2 Celebrex: Sales Forecast ($m), 2010-2025 Figure 6.3 Voltaren: Sales Forecast ($m), 2010-2025 Figure 6.4 Arcoxia: Sales Forecast ($m), 2010-2025 Figure 6.5 Loxonin: Sales Forecast ($m), 2010-2025 Figure 6.6 Mobic: Sales Forecast ($m), 2010-2025 Figure 6.7 Others Agents: Sales Forecast ($m), 2010-2025 Figure 7.1 The Global Anti-Migraine Market: Sales Forecast ($m), 2010-2025 Figure 7.2 Imitrex/Imigran Sales Forecast ($m), 2010-2025 Figure 7.3 Maxalt Sales Forecast ($m), 2010-2025 Figure 7.4 Zomig Sales Forecast ($m), 2010-2025 Figure 7.5 Relpax Sales Forecast ($m), 2010-2025 Figure 7.6 Other Agents: Sales Forecast ($m), 2010-2025 Figure 8.1 Global Anti-Epileptic Market: Sales Forecast ($m), 2010-2025 Figure 8.2 Lyrica Sales Forecast ($m), 2010-2025 Figure 8.3 Topamax Sales Forecast ($m), 2010-2025 Figure 8.4 Others Agents: Sales Forecast ($m), 2010-2025 Figure 8.5 Global Local Anaesthetic Sales Forecast ($m), 2010-2025 Figure 8.6 Lidoderm Sales Forecast ($m), 2010-2025 Figure 8.7 Other Agents: Sales Forecast ($m), 2010-2025 Figure 10.1 Global Pain Market Shares (%) by Region, 2009 Figure 10.2 Countries Leading the Global Pain Market ($m), 2009 Figure 10.3 US, Germany and Other Countries: Sales Forecasts ($m), 2010-2025 Figure 10.4 European, Canadian and Japanese Sales Forecasts ($m), 2010-2025 Figure 10.5 Global Pain Market Shares (%) by Country, 2009 Figure 10.6 Global Pain Market Shares (%) by Country, 2015 Figure 10.7 Global Pain Market Shares (%) by Country, 2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
